06/14/22 1:50 AMOTC, Nasdaq : EVOTF, EVO Evotec Enters a Drug Discovery Collaboration with JanssenEvotec SE (FRA:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO) announced today that the Company has entered a drug discovery collaborationRHEA-AIvery positive
05/19/22 1:50 AMNasdaq, OTC : EVO, EVOTF Evotec and Almirall Enter into a Multi-Target Alliance in Medical DermatologyTHE MULTI-TARGET RESEARCH AND DEVELOPMENT PARTNERSHIP WILL FOCUS ON SEVERE SKIN DISEASES, INCLUDING IMMUNE-MEDIATED INFLAMMATORY CONDITIONS SUCH AS ATOPIC DERMATITIS AND NON-MELANOMA SKIN CANCER SUCH AS BASAL CELL CARCINOMA THE COLLABORATION LEVERAGES EVOTEC'S DATA-DRIVEN EVO IR&D PLATFORM FORRHEA-AIneutral
04/12/22 1:45 AMOTC, Nasdaq : EVOTF, EVO earningsEvotec SE Fiscal Year 2021 Results: 'Setting the Pace' on the Data-Driven R&D Autobahn to CuresSTRONG FINANCIAL RESULTS: 23% INCREASE IN GROUP REVENUES SIGNIFICANTLY EXCEEDING GUIDANCE DATA-DRIVEN PLATFORMS AND TECHNOLOGIES INCREASE PROBABILITIES OF SUCCESS IN ALL MODALITIES SUBSTANTIALLY STRENGTHENED BALANCE SHEET PROVIDING VERY GOOD FOUNDATION AND LEVERAGE FOR SUSTAINABLE, LONG-TERM GROWTHRHEA-AIpositive
04/08/22 1:55 AMOTC, Nasdaq : EVOTF, EVO Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers SquibbEvotecRHEA-AIpositive
01/11/22 2:00 AMOTC, Nasdaq : EVOTF, EVO Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include New Targeted Protein Degradation ApproachJanuary 11,RHEA-AIneutral
01/03/22 1:55 AMOTC, Nasdaq : EVOTF, EVO covid-19Evotec Receives € 7.5 m Grant for Development of COVID-19 TherapeuticEVOTEC RECEIVES A € 7.5 M GRANT FROM THE GERMAN FEDERAL MINISTRY OF EDUCATION AND RESEARCH ("BMBF") FOR THE DEVELOPMENT OF A THERAPEUTIC AGAINST COVID-19 EVOTEC IS DEVELOPING A HIGHLY POTENT IMMUNOMODULATORY MOLECULE THAT HOLDS THE POTENTIAL TO AMPLIFY THE IMMUNE RESPONSE AND REDUCE THE RISK OFRHEA-AIpositive
